Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor Mutational Burden Testing in Solid Tumors.

JAMA oncology - 1 Dec 2023

Kwon Regina, Cheng Heather H, Pritchard Colin C

Abstract excerpt

A 58-year-old man with diabetes, chronic kidney disease, and JAK2-positive myeloproliferative neoplasm is referred for newly diagnosed oligometastatic prostate cancer with substantial urinary symptoms. What would you do next?

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mutational Analysis
Share to Janus Kinase 2
Share to Mutation
Share to Myeloproliferative Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Source

Identifiers

PMID: 37883072
DOI: 10.1001/jamaoncol.2023.4293

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Tumor Mutational Burden Testing in Solid Tumors.PMID 37883072Read ↗

Molecular profiling of solid tumors by next generation sequencing and challenges faced in the healthcare settingSemantic proximity Read ↗

Molecular testing of solid tumors.Semantic proximity Read ↗

Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer.Semantic proximity Read ↗

Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers.Semantic proximity Read ↗

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicSemantic proximity Read ↗

[Ⅱ. Multigene Panel Testing for Musculoskeletal Tumors].Semantic proximity Read ↗

Real-world patterns on tumor mutation burden testing in a pan-tumor population.Semantic proximity Read ↗

Update on immunohistochemistry in bone and soft tissue tumors: Cost-effectively replacing molecular testing with immunohistochemistrySemantic proximity Read ↗

Assessing Limit of Detection in Clinical Sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.